Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12726886 | 0.84 | LMNA (0.51) | LMNAPKMCYP2D6POLBTSHR | |
| SCHEMBL21670323 | 0.81 | LMNA (0.56) | LMNAPKMPOLBTSHRTP53 | |
| SCHEMBL9034156 | 0.78 | LMNA (0.53) | LMNAPKMPOLBTSHRTP53 | |
| SCHEMBL14837754 | 0.78 | LMNA (0.53) | LMNAPKMALDH1A1POLBTSHR | |
| SCHEMBL7025605 | 0.78 | TP53 (0.59) | LMNAPKMPOLBTP53SLC6A9 | |
| SCHEMBL16511272 | 0.77 | SLC6A9 (0.57) | LMNAPKMPOLBTP53SLC6A9 | |
| SCHEMBL24477715 | 0.77 | LMNA (0.55) | LMNAPKMPOLBTP53 | |
| Hydrochloric Acid SCHEMBL1181300 | 0.77 | LMNA (0.52) | LMNAPKMALDH1A1POLBTSHR | |
| SCHEMBL9400522 | 0.77 | LMNA (0.52) | LMNAPKMPOLBTSHRTP53 | |
| SCHEMBL7137676 | 0.77 | POLB (0.54) | LMNAPKMPOLBTP53SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993563-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | LMNA 1065/4885PKM 361/4885ALDH1A1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.